Invention Grant
US08404839B2 Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
有权
4-（3-氯-2-氟苯胺基）-7甲氧基-6 - {[1-（N-甲基氨基甲酰基甲基）哌啶-4-基]氧基}喹唑啉二磺酸甲酯形式A
![Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A](/docs/US/2013-03-26/US08404839B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
- Patent Title (中): 4-（3-氯-2-氟苯胺基）-7甲氧基-6 - {[1-（N-甲基氨基甲酰基甲基）哌啶-4-基]氧基}喹唑啉二磺酸甲酯形式A
-
Application No.: US13273392Application Date: 2011-10-14
-
Publication No.: US08404839B2Publication Date: 2013-03-26
- Inventor: Andrew Hornby Dobson
- Applicant: Andrew Hornby Dobson
- Applicant Address: GB Alderley Park, Macclesfield, Cheshire
- Assignee: Astrazeneca AB
- Current Assignee: Astrazeneca AB
- Current Assignee Address: GB Alderley Park, Macclesfield, Cheshire
- Agency: Astrazeneca AB
- Main IPC: A61K31/517
- IPC: A61K31/517
![Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A](/abs-image/US/2013/03/26/US08404839B2/abs.jpg.150x150.jpg)
Abstract:
4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of the difumarate are described.
Public/Granted literature
- US20120035363A1 CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... Public/Granted day:2012-02-09
Information query
IPC分类:
